Stay updated with breaking news from Initiation Visit. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
10.04.2023 - FREMONT, CA, April 10, 2023 (GLOBE NEWSWIRE) - via NewMediaWire - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that ... Seite 1
/PRNewswire/ -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS,...
ADELAIDE, AUS, June 4, 2021 - (ACN Newswire) - The leading Australian CRO for biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award recipient Avance Clinical announced the results of their
Avance Clinical Expands Gene Technology Clinical Trial Services to Meet $17.4 billion Market Demand The leading Australian CRO Avance Clinical, has expanded its gene technology clinical trial services to meet the increasing global demand predicted to reach $17.4 billion by 2023. BriefingWire.com, 5/09/2021 - ADELAIDE, AUS, May 7, 2021 - (ACN Newswire) - The leading Australian CRO for biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner, Avance Clinical, has expanded its gene technology clinical trial services to meet th...
Avance Clinical Expands Gene Technology Clinical Trial Services to Meet $17.4 billion Market Demand ADELAIDE, AUS, May 7, 2021 - (ACN Newswire) - The leading Australian CRO for biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner, Avance Clinical, has expanded its gene technology clinical trial services to meet the increasing global demand predicted to reach $17.4 billion by 2023. Avance Clinical is accredited as a gene technology CRO under the Office of the Gene Technology Regulator (OGTR). This accreditation recognizes that Avance Clinical has the CRO resources and ...